MENU

Articles by associate14

SignaBlok to Present Preclinical Data on TREM-1-Targeting Drug for the Treatment of Sepsis, Pulmonary Inflammation and Fibrosis at the Respiratory Innovation Summit (RIS) and American Thoracic Society (ATS) International Conference 2025

2025-03-28 // 0 Comments

SignaBlok will present groundbreaking positive preclinical data detailing therapeutic activity of its leading macrophage-restricted TREM-1 inhibitor in experimental sepsis, acute respiratory distress syndrome (ARDS), and [read full press release…]

1 2 3 28
Express Press Release Distribution